Coronavax

About Coronavax

Coronavax, Inc., is a Biotechnology company in Orange, CA, developing a new immunotherapy for Long COVID. Long COVID is a critical unmet medical need, with an estimated 20 Million persons and 100 Million worldwide suffering from the condition. Currently, there are few effective treatments available for Long COVID, with rehabilitative care helping people recover. Cancer immunotherapy has become a success for patients and investors. Instead of highly toxic chemotherapy drugs, this new technology teaches the immune system how to locate, recognize, and kill tumor cells. Each year, immunotherapy approaches have gained regulatory approval for new types of cancer. The leading theory behind Long COVID is that in many cases, the SARS-2 virus is not being eliminated from the body. Infections like HIV and Herpes, and Epstein-Barr virus are examples where the immune response is unable to clear the infection. At Coronavax, we are applying the science of cancer immunotherapy to Long COVID. Our lead product, CVAX-001, is a Lipid Nanoparticle containing SARS-2 spike proteins from three major strains. CVAX-001 is administered via intranasal spray to induce anti-inflammatory mucosal responses. The goal is to eliminate infected cells and residual virus without triggering excess inflammation. CVAX-001 has been manufactured and tested in mice and hamsters. It has not been tested in human clinical trials. We believe that by applying the science of immunotherapy to Long COVID, we can help millions of people to resume a normal, healthy life.

View contact profiles from Coronavax